FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564762571> ?p ?o ?g. }

• W2564762571 endingPage "20" @default.
• W2564762571 startingPage "13" @default.
• W2564762571 abstract "Purpose A retrospective study was conducted to evaluate the time to discontinuation (TTD) of the first- (FGAs) and second-generation antipsychotics (SGAs). Methods In total, 918 treatment episodes of patients with schizophrenia, initiated on one of the investigated drugs on an outpatient basis during 2004–2006, were entered into the study. The primary outcome was the duration of the investigated treatment episode. Discontinuation was defined when either patients were admitted or the investigated drug had been stopped for more than 28 days. We used the Cox proportional hazard model to compare hazards of discontinuations among 8 SGAs versus 2 FGAs (haloperidol and sulpiride). The follow-up period was up to 18 months. Results During the follow-up period, clozapine had the highest rate of continuous treatment in the primary analysis: clozapine, 40.6%; olanzapine, 23.4%; aripiprazole, 22.9%; amisulpride, 21.9%; zotepine, 21.3%; sulpiride, 17.0%; risperidone, 12.8%; quetiapine, 12.5%; haloperidol, 10.6%; and ziprasidone, 10.4%. Compared with haloperidol, 5 SGAs had significantly longer TTD (adjusted hazard ratios and 95% confidence intervals): clozapine (0.403, 0.267–0.607), olanzapine (0.611, 0.439–0.849), aripiprazole (0.570, 0.407–0.795), amisulpride (0.680, 0.487–0.947), and zotepine (0.687, 0.497–0.948), but only clozapine had significantly longer TTD compared with sulpiride (0.519, 0.342–0.786). The sensitivity analysis showed similar results. Implications/Conclusions The current findings suggested that SGAs or FGAs are not homogeneous groups. Clozapine has the highest rate of continuous treatment among SGAs, and haloperidol is not the representative drug for all FGAs. Furthermore, antipsychotics dropout rate is high in naturalistic situation. A good service model needs to be constructed to enhance antipsychotic treatment adherence of people with schizophrenia." @default.
• W2564762571 created "2017-01-06" @default.
• W2564762571 creator A5001741974 @default.
• W2564762571 creator A5062675058 @default.
• W2564762571 creator A5068479690 @default.
• W2564762571 creator A5001692343 @default.
• W2564762571 date "2017-02-01" @default.
• W2564762571 modified "2023-09-26" @default.
• W2564762571 title "Time to Discontinuation of Second-Generation Antipsychotics Versus Haloperidol and Sulpiride in People With Schizophrenia" @default.
• W2564762571 cites W1496843021 @default.
• W2564762571 cites W1787454655 @default.
• W2564762571 cites W1868854066 @default.
• W2564762571 cites W1964920874 @default.
• W2564762571 cites W1973562905 @default.
• W2564762571 cites W1980143549 @default.
• W2564762571 cites W1984517026 @default.
• W2564762571 cites W1991475958 @default.
• W2564762571 cites W1991545482 @default.
• W2564762571 cites W2003289380 @default.
• W2564762571 cites W2016117636 @default.
• W2564762571 cites W2025924280 @default.
• W2564762571 cites W2035752332 @default.
• W2564762571 cites W2036121762 @default.
• W2564762571 cites W2039549833 @default.
• W2564762571 cites W2041474698 @default.
• W2564762571 cites W2044398915 @default.
• W2564762571 cites W2045948341 @default.
• W2564762571 cites W2047750072 @default.
• W2564762571 cites W2050173051 @default.
• W2564762571 cites W2051108113 @default.
• W2564762571 cites W2053550022 @default.
• W2564762571 cites W2070893229 @default.
• W2564762571 cites W2083472099 @default.
• W2564762571 cites W2085360366 @default.
• W2564762571 cites W2089555882 @default.
• W2564762571 cites W2095714789 @default.
• W2564762571 cites W2103557560 @default.
• W2564762571 cites W2109070861 @default.
• W2564762571 cites W2111105929 @default.
• W2564762571 cites W2152770536 @default.
• W2564762571 cites W2159155203 @default.
• W2564762571 cites W2162391751 @default.
• W2564762571 cites W4254771839 @default.
• W2564762571 doi "https://doi.org/10.1097/jcp.0000000000000623" @default.
• W2564762571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27977467" @default.
• W2564762571 hasPublicationYear "2017" @default.
• W2564762571 type Work @default.
• W2564762571 sameAs 2564762571 @default.
• W2564762571 citedByCount "16" @default.
• W2564762571 countsByYear W25647625712017 @default.
• W2564762571 countsByYear W25647625712019 @default.
• W2564762571 countsByYear W25647625712020 @default.
• W2564762571 countsByYear W25647625712021 @default.
• W2564762571 countsByYear W25647625712022 @default.
• W2564762571 countsByYear W25647625712023 @default.
• W2564762571 crossrefType "journal-article" @default.
• W2564762571 hasAuthorship W2564762571A5001692343 @default.
• W2564762571 hasAuthorship W2564762571A5001741974 @default.
• W2564762571 hasAuthorship W2564762571A5062675058 @default.
• W2564762571 hasAuthorship W2564762571A5068479690 @default.
• W2564762571 hasConcept C118552586 @default.
• W2564762571 hasConcept C126322002 @default.
• W2564762571 hasConcept C137183658 @default.
• W2564762571 hasConcept C15744967 @default.
• W2564762571 hasConcept C207103383 @default.
• W2564762571 hasConcept C2776412080 @default.
• W2564762571 hasConcept C2776619155 @default.
• W2564762571 hasConcept C2777270317 @default.
• W2564762571 hasConcept C2778715236 @default.
• W2564762571 hasConcept C2778999636 @default.
• W2564762571 hasConcept C2780057945 @default.
• W2564762571 hasConcept C2780211496 @default.
• W2564762571 hasConcept C2780634440 @default.
• W2564762571 hasConcept C2780806966 @default.
• W2564762571 hasConcept C2780864610 @default.
• W2564762571 hasConcept C2780948584 @default.
• W2564762571 hasConcept C44249647 @default.
• W2564762571 hasConcept C513476851 @default.
• W2564762571 hasConcept C71924100 @default.
• W2564762571 hasConceptScore W2564762571C118552586 @default.
• W2564762571 hasConceptScore W2564762571C126322002 @default.
• W2564762571 hasConceptScore W2564762571C137183658 @default.
• W2564762571 hasConceptScore W2564762571C15744967 @default.
• W2564762571 hasConceptScore W2564762571C207103383 @default.
• W2564762571 hasConceptScore W2564762571C2776412080 @default.
• W2564762571 hasConceptScore W2564762571C2776619155 @default.
• W2564762571 hasConceptScore W2564762571C2777270317 @default.
• W2564762571 hasConceptScore W2564762571C2778715236 @default.
• W2564762571 hasConceptScore W2564762571C2778999636 @default.
• W2564762571 hasConceptScore W2564762571C2780057945 @default.
• W2564762571 hasConceptScore W2564762571C2780211496 @default.
• W2564762571 hasConceptScore W2564762571C2780634440 @default.
• W2564762571 hasConceptScore W2564762571C2780806966 @default.
• W2564762571 hasConceptScore W2564762571C2780864610 @default.
• W2564762571 hasConceptScore W2564762571C2780948584 @default.
• W2564762571 hasConceptScore W2564762571C44249647 @default.
• W2564762571 hasConceptScore W2564762571C513476851 @default.
• W2564762571 hasConceptScore W2564762571C71924100 @default.

• next